Alec Stranahan
Stock Analyst at B of A Securities
(0.57)
# 4,154
Out of 5,154 analysts
33
Total ratings
34.62%
Success rate
-53.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $288 → $318 | $253.69 | +25.35% | 6 | Jan 22, 2026 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $4.94 | +41.70% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $11.32 | +6.01% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $15.47 | -93.54% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $9.98 | -29.86% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $26.54 | +58.25% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $21.20 | +17.92% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.82 | +504.40% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $4.97 | +20.72% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.00 | +650.00% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $98.40 | -44.11% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $29.27 | -79.50% | 2 | Dec 29, 2022 |
Krystal Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $288 → $318
Current: $253.69
Upside: +25.35%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $4.94
Upside: +41.70%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $11.32
Upside: +6.01%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $15.47
Upside: -93.54%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $9.98
Upside: -29.86%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $26.54
Upside: +58.25%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $21.20
Upside: +17.92%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.82
Upside: +504.40%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $4.97
Upside: +20.72%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.00
Upside: +650.00%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $98.40
Upside: -44.11%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $29.27
Upside: -79.50%